Jehovah's witnesses generally refuse red and white blood cells, platelets and plasma even at the cost of their lives. So-called minor fractions of blood such as albumin and globulin, fractions or parts derived from prohibited components, and cadaveric organs are permitted as a matter of personal choice. 1 This refusal will greatly affect treatment options for Jehovah's witnesses with leukaemia. In spite of this refusal, there have been a number of reports of Jehovah's witnesses with leukaemia receiving aggressive chemotherapy or autologous bone marrow transplantation, which were recently reviewed by Walsh and Bevan. 5 Here, we report the case of a Jehovah's witness with CML, who underwent matched sibling allogeneic stem cell transplantation (SCT) after a minimally myelosuppressive-conditioning regimen.
Case report
A 43-year-old female Jehovah's witness was diagnosed with chronic myelogenous leukaemia in January 2001. She was initially treated with hydroxyurea and the patient and siblings were HLA-typed. One sister was found to be HLA-A,-B, -C, -DR, and -DQ identical and the possibility of a sibling allogeneic blood SCT was discussed with the patient. After counselling about the different treatment options, the patient discussed the issue with her congregation. They concurred that peripheral blood stem cells mobilized by G-CSF were an organ and therefore acceptable.
At the time, HLA-identical sibling allogeneic SCT with conventional conditioning would have been the treatment of choice, but this was considered unacceptable because the patient declined 'blood' transfusions. We therefore suggested allogeneic SCT after a reduced-intensity-conditioning regimen with reportedly minimal myelosuppression 2 and additional erythropoietin treatment to reduce the risk of anaemia.
In November 2001, the patient underwent HLA-identical peripheral blood SCT (PBSCT) (8.1 Â 10 6 CD34+ cells/kg bodyweight; 5.16 Â 10 8 CD3+ cells/kg bodyweight) after reduced-intensity conditioning with 2 Gy total body irradiation (TBI) (day -7) and fludarabine 3 Â 30 mg/m 2 (days -5 to -3). The patient was treated with 50 mg darbepoetin alfa s.c once weekly starting from day -19 to discharge. Graft-versus-host disease (GvHD) prophylaxis consisted of 2 Â 1 g mycophenolate mofetil (MMF) (until day 28) and cyclosporine (CSA) 6 mg/kg (targeted to the range of 200-220 mg/l) starting day -1 (Figure 1 ). Conditioning and the period after transplantation were uneventful, the haemoglobin level and platelet count did not reach our cutoff for transfusion requirements, and the patient was discharged on day 15 after PBSCT ( Figure 2) . Cyclosporin was slowly tapered from day +77 and discontinued on day +121. At 1 week after CSA discontinuation, the patient developed chronic GvHD (skin, gut, lung), which was well controlled after treatment with mycophenolate mofetil, prednisolone, and budesonide ( Figure 1 ). Molecular response and donor/ recipient chimerism were routinely monitored. Bcr/abl copies as detected by quantitative and nested PCR fell over a period of 6 months before being undetectable (Figure 1 ). Complete donor chimerism was achieved 5 months after PBSCT. The patient continues to be in molecular remission without relevant chronic GvHD (nested PCR negative four times) ( Figure 1 ). with CML and may indeed cure patients with this disease. 2, 3 To our knowledge, this is the first case of an allogeneic SCT for a Jehovah's witness with CML. There is only one other case of a Jehovah's witness undergoing allogeneic SCT in the literature. Mazza et al 4 report an 11-year-old boy with T-ALL who underwent matched sibling allogeneic bone marrow transplantation after conditioning with TBI and cyclophosphamide without receiving transfusions. 5 No further details concerning treatment, complete blood counts or complications are conveyed. In our view, a conventional allogeneic stem cell transplant would not be an option for a Jehovah's witness who refuses platelet or erythrocyte transfusions because of the inherent risks of uncontrollable bleeding and anaemia.
When treating Jehovah's witnesses with a haematological malignancy or other haematological diseases that may be cured by allogeneic SCT, the approach described in this case report should be kept in mind. Allogeneic SCT afterreduced-intensity conditioning should be considered for patients with malignancies for which the graft-versusleukaemia effect is well documented (eg CML, multiple myeloma, low-grade lymphoma) or diseases that can be cured solely by achieving full donor chimerism (eg inborn errors of metabolism, SAA). With an estimated 6 million Jehovah's witnesses worldwide, a problem similar to the current case may be encountered by any practising haematologist. 5 The question of whether G-CSF mobilized peripheral blood stem cells are to be considered a blood transfusion or an organ is probably philosophical, but this was fortunately decided by the patient and her congregation. 
